Volume 18

Issue 1

Article 18

PASSIVE IMMUNITY TO WHITE SPOT SYNDROME VIRUS (WSSV) IN
PENAEUS MONODON TREATED WITH MONOCLONAL ANTIBODIES OF THE
HETEROLOGOUSLY PRODUCED VP28 VIRAL ENVELOPE PROTEIN
Jyh-Yih Chen
Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10, Dahuen Rd., Jiaushi,
Ilan 262, Taiwan

Kumarasamy Anbarasu
Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, 23-10, Dahuen Rd., Jiaushi,
Ilan 262, Taiwan

Chin-Yu Chen
Han Te Biotechnology Co., 24 Fl., 29 Jungjeng E. Rd., Sec. 2, Danshuei, Taipei 251, Taiwan

Ying-Chuan Lee
Han Te Biotechnology Co., 24 Fl., 29 Jungjeng E. Rd., Sec. 2, Danshuei, Taipei 251, Taiwan

Fan-Hua Nan
Department of Aquaculture, National Taiwan Ocean University, Keelung 202, Taiwan.
See next page for additional authors

Follow this and additional works at: https://jmstt.ntou.edu.tw/journal
Part of the Aquaculture and Fisheries Commons

Recommended Citation
Chen, Jyh-Yih; Anbarasu, Kumarasamy; Chen, Chin-Yu; Lee, Ying-Chuan; Nan, Fan-Hua; and Kuo, Ching-Ming (2010)
"PASSIVE IMMUNITY TO WHITE SPOT SYNDROME VIRUS (WSSV) IN PENAEUS MONODON TREATED WITH
MONOCLONAL ANTIBODIES OF THE HETEROLOGOUSLY PRODUCED VP28 VIRAL ENVELOPE PROTEIN," Journal of
Marine Science and Technology: Vol. 18: Iss. 1, Article 18.
DOI: 10.51400/2709-6998.1876
Available at: https://jmstt.ntou.edu.tw/journal/vol18/iss1/18
This Research Article is brought to you for free and open access by Journal of Marine Science and Technology. It has been
accepted for inclusion in Journal of Marine Science and Technology by an authorized editor of Journal of Marine Science and
Technology.

PASSIVE IMMUNITY TO WHITE SPOT SYNDROME VIRUS (WSSV) IN PENAEUS
MONODON TREATED WITH MONOCLONAL ANTIBODIES OF THE
HETEROLOGOUSLY PRODUCED VP28 VIRAL ENVELOPE PROTEIN
Acknowledgements
This work was funded by a grant from the Marine Research Station, Institute of Cellular and Organismic
Biology, Academia Sinica, Jiaushi, Ilan

Authors
Jyh-Yih Chen, Kumarasamy Anbarasu, Chin-Yu Chen, Ying-Chuan Lee, Fan-Hua Nan, and Ching-Ming Kuo

This research article is available in Journal of Marine Science and Technology: https://jmstt.ntou.edu.tw/journal/
vol18/iss1/18

Journal of Marine Science and Technology, Vol. 18, No. 1, pp. 145-152 (2010)

145

PASSIVE IMMUNITY TO WHITE SPOT
SYNDROME VIRUS (WSSV) IN PENAEUS
MONODON TREATED WITH MONOCLONAL
ANTIBODIES OF THE HETEROLOGOUSLY
PRODUCED VP28 VIRAL ENVELOPE PROTEIN
Jyh-Yih Chen*, Kumarasamy Anbarasu*, Chin-Yu Chen**, Ying-Chuan Lee**,
Fan-Hua Nan***, and Ching-Ming Kuo*
Key words: white spot syndrome virus, Penaeus monodon, monoclonal antibody, immersion, oral administration.

ABSTRACT
White spot syndrome virus (WSSV) is a highly pathogenic
and prevalent virus affecting shrimp culture worldwide including Taiwan. In the present study, the viral envelope protein, VP28, gene of the WSSV was cloned into a pET28a
expression vector. VP28 was expressed as a protein with a
6-histidine tag in Escherichia coli and purified by a Ni-NTA
column. Antiserum was raised against this recombinant VP28
protein in BALB/C mice, and it recognized the VP28 protein
in purified virions and recombinant proteins. The antiserum
was mixed with arginine (100 ppm), lysine (168 ppm), and
phenylalanine (88 ppm), and the titer of the antibody was
20,000-fold/ml. A series of monoclonal antibodies was tested
for their ability to neutralize WSSV infectivity by immersion
and oral administration. Our results proved that the antibody
developed against the VP28 protein could efficiently prevent
or control WSSV infection in post-larval and juvenile stages
by immersion and oral administration. Furthermore, the postlarvae obtained from the antibody-treated group had > 60%
survival after 20 days of challenge, illustrating that the antibody produced from heterologously expressed VP28 may specifically provide passive immunity against the WSSV pathogen. Therapeutic studies illustrated that shrimp losses could
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be controlled within 5 days of infection using this monoclonal
antibody. These results should be considered in the light of the
potential application of anti-VP28 antibodies as a prophylactic
drug in aquaculture.

I. INTRODUCTION
Penaeus monodon has experienced many disease challenges in the aquaculture industry. One of the most significant
of these is the white spot syndrome virus (WSSV) infection,
and larvae and juveniles always carry the virus from their
parents. Outbreaks of white spot disease (WSD) in cultured
penaeid shrimp infected with the WSSV have caused mass
mortality and serious economic losses worldwide. The mortality can reach 100% within 3~10 d after an infection in
shrimp populations. In Taiwan, the first case report of epizootic disease was in 1992, followed by Japan in 1993, and
China in 1995 [11, 3]. To the present, no solutions have completely controlled this viral disease.
To date, no effective prophylactic treatment measures are
available for viral infections in shrimp and other crustaceans.
A previous study reported that VP28 is a polypeptide with a
predicted size of 22 kDa and no significant similarity with
other known proteins [2]. van Hulten et al. observed that incubation of the WSSV with rabbit polyclonal anti-VP28 serum
lessened the mortality of live P. monodon [16]. Those above
data and a report by Zhang et al. which suggested that VP28 is
associated with the outer surface of intact WSSV virions indicate that VP28 can stimulate shrimp immunity to WSSV
infection [22, 14].
Because the WSSV has such a wide host range and not only
infects shrimp species but also many other crustaceans [9],
developing new treatment methods is of the greatest urgency
for aquaculture. Hence, developing a way of vaccinating
shrimp against WSSV would be desirable. A previous publication on the copepod Macrocyclops albidus showed that a
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specific memory may exist in the defense system of this invertebrate species, which reacted more efficiently after encountering an antigenic parasite [7]. Extracted plasma from
surviving shrimp after a WSSV infection can be used to neutralize WSSV from 20 to 60 days after infection [18]. These
results suggest that an adaptive immune response may exist in
shrimp, and protection against WSSV can possibly be induced
in shrimp by a vaccination. Furthermore, a strategy was developed and adopted for protecting P. monodon against WSSV
by oral vaccination [14]. Recently, a few studies have made
efforts to develop polyclonal antibodies (pAbs) against specific viral peptides such as VP28 and VP19 and have obtained
promising results with indoor experiments [17, 8]. Nevertheless, considering all these previous reports, in the present
study, a monoclonal antibody (mAb) was developed against
the VP28 peptide alone in high titers using hybridoma technology with a mouse model, and its prophylactic and treatment
efficiencies were evaluated via immersion and oral routes in P.
monodon, a highly susceptible species to WSSV.

II. THE TRANSCEIVER STRUCTURE
1. Experimental Shrimp and Rearing Conditions
In the present study, about 120,000 post-larvae (PL 15)
were obtained from a shrimp hatchery in Pingtung, southern
Taiwan, and transported to the Marine Research Station, Ilan,
northern Taiwan by air and road transport in aerated bags.
Upon arrival, they were randomly separated into eight 3000-L
fiberglass tanks (200 m wide x 80 m high) each containing
about 15,000 post-larvae, which were acclimatized and reared
in ozone-treated seawater. In the rearing tank, the temperature
(26.4 ± 1.4°C), pH (8.06 ± 0.26), and DO (8.00 ± 0.4 mg/L)
were recorded every day. Moreover, adequate continuous aeration and an open water system were maintained throughout the
experiment. Sixty-day-old post-larvae from the control tank
were considered juveniles (1.25 ± 0.27 g in weight and 4.12 ±
0.31 cm in length) for determining the WSSV titration, and the
challenge and therapeutic experiments. They were maintained
in 50-L glass aquariums with open-water circulation and a
continuous aeration system. They were fed ad libitum with
commercially available prawn feed twice a day (at 8% of their
body weight). The uneaten food and nitrogenous waste materials were siphoned out every day.
2. WSSV Stock and Antigen
The WSSV stock used in the present study was prepared
from WSSV-infected tiger shrimp (P. monodon) which had
predominant white spots on the exoskeleton and which were
PCR-positive for the virus. The hepatopancreas and exoskeleton were collected and ground in 1x TN buffer (20 mM
Tris-Base and 400 mM NaCl; pH 7.4) at 0.25 mg/ml and centrifuged at 10,000 rpm for 10 min at 4°C; the supernatant was
filtered (0.45 µm) to remove impurities, followed by ultracentrifugation in a CsCl density gradient (20%, 30%, and

40%); then it was resuspended in 1x TN buffer and centrifuged
again at 39,000 rpm and 4°C for 18 h. The solution was digested with proteinase K (100 µg/ml) and a 1/10 volume of
lysis buffer (100 mM Tris-HCl (pH 8.0), 100 mM EDTA, and
2.5% SDS) and incubated at 55°C for 24 h. WSSV DNA was
obtained by the phenol chloroform extraction method. Using
the polymerase chain reaction (PCR), the VP28 envelope gene
was amplified and sequenced.
3. Cloning, Expression, and Purification of the Antigen
The PCR-amplified VP28 fragment was eluted and purified
after agarose gel electrophoresis. This DNA fragment (translated to a truncated VP28 protein) was cloned into the pET 28a
vector, ligated, and transformed into Escherichia coli. The
PCR primer design followed that of Witteveldt et al. [14]. The
transformants were cultivated at 37°C for 3 h, followed by the
addition of 1 M isopropyl-β-d-thiogalactopyranoside (IPTG)
to a final concentration of 1 mM to induce protein expression
for another 3 h at 37°C with continuous shaking. The VP28
antigen protein was purified by His-tag metal affinity column
chromatography with Ni-NTA agarose beads.
4. Production of the mAb
The purified soluble antigen was used to produce the mAb
in 6~8-week-old healthy BALB/C mice. The antigen (100 µg)
was emulsified with an equal volume of Freund’s complete
adjuvant (FCA) and injected intraperitoneally into the abdominal cavity. After 3 weeks, a booster dose was given at the
same site and dose using Freund’s incomplete adjuvant (FIA)
prepared as described above. Three weeks later, a final injection was given with no adjuvant. Blood was drawn from a tail
vein after 1 week, and the titers were determined by an enzyme-linked immunosorbent assay (ELISA). Before cell fusion, the BALB/C control mice were sacrificed, soaked in
75% ethanol, cleaned with iodine, and the abdominal cavity
opened. Then 5 ml of HAT select medium containing fetal
bovine serum (FBS) was injected into the abdominal cavity.
After 10 min, the medium was aspirated, diluted with 5 ml of
fresh HAT medium, distributed into a 96-well ELISA plate,
and incubated at 37°C with 5% CO2; after fusion (days 3 and
4), the medium was changed.
In order to identify potential clones, all fusion-cloned hybridoma cells were screened by an ELISA. Purified antigen
proteins (VP28) were diluted with 0.05 M sodium carbonate
buffer (0.159% (w/v) sodium carbonate and 0.293% (w/v)
sodium bicarbonate; pH 9.6) to obtain 10 µg/ml, and were
added to each well in a 96-well ELISA plate. The plate was
covered, incubated at 4°C overnight, and blocked with bovine
serum albumin (BSA) at 37°C for 1 h. The antigen solution
was dumped out and washed with phosphate buffer (pH 7.4) 3
times, each time for 3~5 min. One hundred microliters of the
hybridoma cell suspension was added to each well, which was
then filled with an equal volume of RPMI 1640, and cultivated
at 37°C for 1~2 h. The plate was again washed with phosphate
buffer (pH 7.4) 3 times, each time for 3~5 min, and 100
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µl/well of the pre-diluted anti-mouse immunoglobulin G (IgG)
enzyme-labeled secondary antibody was added, incubated at
37°C for 1~2 h, and washed 3 times again. Finally, 100
µl/well of the OPD-peroxidase substrate was added and incubated at room temperature for 30 min without light. After
color development, 50 µl of a stop solution (2 M sulfuric acid)
was added to each well, and the solutions were examined in
an ELISA reader at 490 nm. Serum (diluted 100-fold) from
immunized mice was used as the positive control, while serum
from myeloma cells was used as the negative control.
Feeder layers were prepared from ascites fluid of healthy
BALB/C mice. Positive hybridomas were diluted (1 clone/
100 µl), distributed in 96-well microtiter plates, and incubated
with 5% CO2 at 37ºC. The medium was changed once every 3
days. The antibody titer was determined after 8~10 days;
positive wells were labeled, and fresh medium was again
added. The mAb was diluted in ratios of 1 × 10-2, 2 × 10-2, 1 ×
10-3, 2 × 10-3, and 1 × 10-4 and analyzed by Western blotting to
confirm the antibody specificity and titer. Briefly, the VP28
protein was transferred to nylon membranes from a sodium
dodecylsulfate polymerase chain reaction (SDS-PAGE) in a
semi-dry blotter (PantherTM Semidry Electroblotter) at 120
mA for 70 min. The membrane was placed in blocking buffer
(5% non-fat milk powder in TBST (20 mM Tris-HCl, 150 mM
NaCl, and 0.05% Tween-20)) for 1 h, washed with TBST
buffer for 5 min, and incubated with 5 ml of blocking buffer
containing primary antibody for 2 h at room temperature (RT).
After hybridization, the membrane was again washed with
TBST for 5 min and incubated with 5 ml of blocking buffer
containing the secondary antibody for 1 h at RT. The membrane was washed twice with TBST for 10 min and washed 3
times with TBS (20 mM Tris-HCl and 150 mM NaCl) for 5
min. Finally, the membrane was developed with 10 ml of APB
staining solution containing nitro blue tetrazolium (NBT) and
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) at room temperature.
5. Immersion and Oral Administration Experiments
In the present study, 4 different experimental trials were
adopted to determine the prophylactic and therapeutic efficiencies of the mAb. The antiserum was mixed with arginine
(100 ppm), lysine (168 ppm), and phenylalanine (88 ppm), and
the titer of antibody was 20,000-fold/ml. A series of mAbs
was tested for their ability to neutralize WSSV infectivity by
immersion and oral administration. The other parameters remained the same throughout the experiment. The water temperature was maintained at 26.4 ± 1.4°C during the entire
experimental period.
Experiment 1
About 150 juveniles were transferred to a 50-L glass tank
and divided into 5 groups in triplicate from the control tank in
experiment 1. They were exposed to different concentrations
of WSSV (group 1, 200 µl; group 2, 300 µl; group 3, 400 µl;
group 4, 500 µl; and group 5, the control; each group contained

Immersion treatment

Day

147

Monitoring survival rate

0 3 7 14 21 28 30 35 42 49 56 60 63

PL 15 put to
culture tank

Monitoring growth rate

Fig. 1. Schematic diagram of the post-larval experimental design.

30 juveniles) through feeding twice a day to determine the
juvenile challenge virus titer. It was prepared by adding appropriate amounts of the virus solution/TN buffer with 1 ml of
seawater, and fed to the shrimp 1 h after incubation. This
condition was maintained until the end of the experiment.
Shrimp mortality was continually monitored (4 times/day) and
recorded.
Experiment 2
The mAb experiments scheduled in the post-larval stage are
diagrammatically presented in Fig. 1. The acclimatized postlarvae (3 days after receiving the mAb, each quantified with
about 15,000 shrimp) were transferred to 4 individual tanks for
1 h of pretreatment with 75 L of seawater with 150 ml of the
antibody for the antibody group, 1.25 ml virulent WSSV for
the virus group, 150 ml antibody + 1.25 ml WSSV for the
antibody + virus group, and seawater alone for the control
group. They were incubated for about an 1 h at 26°C, and then
returned to the 3000-L rearing tanks. They were fed commercially available powdered feed (P-1) for the first 30 days
and P-2 for the subsequent duration at about 8% of their body
weight 4 times a day. On 2 occasions, 15 ml of antibody was
mixed with feed for the antibody and antibody + virus groups
and incubated for 1 h before feeding to allow the antibody to
adhere to the feed, while for the virus and control groups, the
feed was only mixed with 15 ml of seawater. The post-larval
cumulative survival and growth rates were determined once at
30 and 60 days or every 7 days for up to 8 weeks, respectively,
until the end of the experiment. This experiment was run in
triplicate.
Experiment 3
Antibody-treated and control juvenile survival rates were
estimated by obtaining juveniles weighing > 1 g fed the PL
feed antibody with feed mixture every day and those from
control tanks with feed but no antibody and divided them into
4 groups for treatment with the antibody (Ab), WSSV virus
(V), antibody + virus (Ab + V), or control (C). Thirty juveniles were maintained in each tank with 3 triplicates. Five
milliliters of antibody and 250 µl of virus were mixed with
feed twice a day. The tanks were kept at room temperature. In
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the control and virus groups, 5 ml of seawater was added.
Juvenile mortality was recorded 4 times a day.
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3

kDa
124

Experiment 4
To determine the therapeutic effect of the mAb, 180 juveniles were taken from the control tank and divided into 6
groups with triplicates; thus, each tank contained 10 juveniles.
Except for the positive control, all other juveniles were exposed to 300 µl of the infective virus on day 0. After 1, 3, 5,
and 7 days, different groups were treated with 5 ml of antibody
twice a day until the end of the experiment. The negative
control group was not treated with antibody. The mortality
was recorded 4 times a day.

80

49

34

6. Statistical Analyses
Statistical analysis was performed using the SAS 8.0 software (Statistical Analysis System) for Windows.

28

III. RESULT
1. Expression of VP28 in the E. Coli Protein Expression
System
Viral DNA was amplified by a PCR and cloned into the
pET28a vector. Five clones were chosen and identified by
sequencing. One of the VP28 clones was transformed into the
E. coli BL21 DE3 strain to induce IPTG. The expressed recombinant VP28 protein was visualized by Coomassie blue
staining after SDS-PAGE and confirmed by reaction with the
mAb (Fig. 2).

20
Fig. 2. Western blot of the virion of WSSV (lane 1, as indicated by the
arrow) purified by CsCl gradient centrifugation and the recombinant VP28 protein (lane 2) of the anti-VP28 monoclonal antibody. Lane 3 is the protein marker. Numbers on the right side
indicate the positions of the protein marker.

120

2. Production and Characterization of mAbs

3. In vivo Test by Immersion and Oral Treatment
In the study of juvenile susceptibility to various WSSV concentrations (Fig. 3), it was demonstrated that 100% mortality
occurred in both groups of juveniles exposed to 400 and 500 µl
on day 10 and to 200 and 300 µl on day 20, which illustrates
that 200~300 µl of WSSV are concentrations to which P.
monodon juveniles are susceptible. Figure 4(a) shows the
post-larval survival 30 and 60 days after immersion and oral
treatment with the mAb. The results clearly illustrate that the
antibody-treated groups had much-higher survival rates than
their untreated counterparts. The antibody- and virus-treated
groups also showed elevated survival rates compared to the
control and virus-treated groups until the end of the experiment, which directly illustrates the efficiency of the mAb
against WSSV during the early stage of development. The

100
Survival ratio (%)

Supernatant fluids from hybridoma cultures were screened
by recombinant VP28 protein based on an ELISA at 2 weeks
after fusion. Finally, 5 clones were shown to have high optical
density (OD) values on an ELISA reader. The mAbs were
identified by Western blotting using the purified virus and
were confirmed to express the recombinant VP28 protein (Fig.
2).

200 μl
300 μl
400 μl
500 μl

80
60
40
20
0
1

5

10

15

20

days post challenge
Fig. 3. Titration of WSSV in Penaeus monodon shrimp. Time postchallenge in days after incubation with different concentrations of
WSSV for 60 min and various days are shown on the abscissa,
and the survival ratio (%) is on the ordinate.

post-larval growth rate (as assessed by weight gain) was also
directly proportional to the results of the survival study (Fig.
4(b)). The antibody-treated group had a significantly elevated
growth rate compared to all other groups; on the other hand,
the antibody + virus-treated groups did not have a significantly
higher growth rate compared to the control, even though the
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(b)
Fig. 4. (a) Time/surviving number relationship of immersion experiment
1. Mortality is expressed as the surviving number on various days
post-challenge. Four groups were treated with the antibody (Ab),
WSSV virus (V), or antibody + virus (Ab + V), or untreated
(control; C). Numbers of animals used in each experiment were
15,000 shrimp. (b) Time/growth rate relationship of immersion
experiment 2. The asterisk (*) indicates a significant difference
from the other treatment groups.

antibody placed together with WSSV may have neutralized
the WSSV’s infective ability. Nevertheless, it was slightly
higher than that of the virus-treated group on almost all sample
days. These results strongly illustrate that the antibody and
healthy control post-larvae grew faster than virus-infected organisms. Furthermore, shrimp given the antibody treatment
after virus infection did not recover the lost weight. These
studies led us to propose 2 hypotheses: prevention is better
than a cure as the non-infected control group and the group
treated by antibody alone grew better than the infected group,
and WSSV infection greatly reduced the growth rate of P.
monodon post-larvae.

0
1

5

10
15
20
days post challenge
(b)

25

30

Fig. 5. (a) Treatment of post-larvae (PL 15) with antibody for 60 min at
26°C by immersion. After this, from the PL 15 stage to juveniles
(weight > 1 g), feed combined with the antibody mix was given
every day. Thirty juvenile shrimp were divided into 4 groups
treated with the antibody (Ab), WSSV virus (V), or antibody +
virus (Ab + V), or untreated (control; C). The percentage survival rate was assessed for different treatment groups. An asterisk (*) indicates a significant difference from the other treatment
groups. (b) Thirty juvenile shrimp were divided into 4 groups
and treated with the antibody (Ab), WSSV virus (V), or antibody +
virus (Ab + V), or untreated (control; C). These experimental
shrimp were treated with no antibody or virus before the experiments. The percentage survival rate was assessed for the different groups during treatment. An asterisk (*) indicates a significant difference from the other treatment groups. (a and b)
Relationship of the survival ratio with the time post-challenge in
days for oral administration in experiment 3.

The results for juveniles (Fig. 5(a)) obtained from the antibody-treated post-larval studies clearly illustrate the efficiency of the mAb treatment against the WSSV pathogen. In
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different experimental groups, the survival exceeded 80% to
the end of the experiment. Groups treated with antibody alone
showed the highest survival followed by the control, then the
antibody + virus-, and virus-treated groups. Interestingly, we
noted a better percentage (75%) of survival in the viruschallenged group up to day 20, after which it rapidly decreased
to 48% on days 25 and 30. This result clearly demonstrates
that with post-larval antibody exposure, juveniles can withstand WSSV infection for a very long time. However, juveniles obtained from the control rearing tank (Fig. 5(b)) showed
no significantly higher survival rates during WSSV challenge.
The results indicate that the antibody-treated groups had better
survival compared to the untreated groups. The virus-challenged
group showed 100% mortality within 10 days, which illustrates that juveniles are also susceptible to WSSV infection,
while the antibody- and virus-treated groups had more than
60% survival to the end of the experiment. These findings
illustrate that the mAb is effective when administered to juveniles via mixing it with feed. Results of the therapeutic
effect of the antibody against WSSV (Fig. 6) clearly demonstrated that both the positive control group and the group
treated with the antibody for 1 day showed better relative
percent survival rates than did the other groups (97% and 93%,
respectively). In the negative control group, 100% mortality
was observed on day 21, and treated groups on days 3 and 5
after treatment showed more than 60% and 50% survival,
respectively, to the end of the experiment (30 days), which
clearly demonstrates that the mAb can be used as a passive
vaccine within 5 days of onset of infection.

IV. DISCUSSION
In the present study, a high-titer mAb was developed against
the WSSV-VP 28 protein in mice by hybridoma technology,
and its efficiency was determined in post-larvae and juveniles
of the WSSV-susceptible tiger shrimp, P. monodon, by immersion and oral administration. These are the most practical
and easiest immunization routes and can be adopted even by
laymen in the field; in addition, these cause only a little stress
to organisms. Even though it is generally believed that invertebrates do not have as well-developed adoptive defense
mechanisms as vertebrates due to the lack of defined lymphoid
organs [6], some scientific reports have, nevertheless, raised
questions about such ideas. For example, it has been reported
that some invertebrates such as P. monodon and P. japonicus
have some level of a memory response against bacteria [1,
4]; that the copepod, Macrocyclops albidus, has a response
against tapeworm parasites [7], Schistocephalus solidus; and P.
monodon responds to viral pathogens [18]. Moreover, the
pAbs recently developed against virus subunits (VP28 and
VP19) were shown to possess the potential to protect P.
monodon, P. chinensis, and crayfish (Cambarus clarkia)
against WSSV infection [5, 8, 14]. Even though no commercial vaccines or mAbs are yet available to prevent or treat
this contagious virus which has caused disease outbreaks
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Fig. 6. Monoclonal antibody therapeutic efficiency after different lengths
(days) of WSSV challenge. Treatment of the 6 groups used are
described in experiment 4. An asterisk indicates a significant
difference from the other treatment groups. NC, only treated
with virus; PC, untreated, i.e., no virus or antibody.

worldwide [19], the developed pAbs against subunit peptides
are widely used for identifying envelope proteins by neutralization assays, ELISA, Western blotting, and immunoelectron
microscopic studies. However, researchers hope that with the
help of the aforementioned pAbs, passive immunization
against WSSV will be possible in shrimp [14]. The present
study is in line with the above concept and is the first attempt
to produce high titers of a mAb against a single WSSV peptide
(VP28) and to determine its prophylactic and therapeutic efficiencies in tiger prawn (P. monodon) post-larvae and juveniles via a natural route.
In the present study, the efficiency of the mAb was measured in post-larvae (PL15) and juveniles, and in the near future,
we plan to perform experiments using all stages and different
routes. Infectivity studies in this context illustrate that all developmental stages of P. monodon, such as nauplii, protozoeae,
zoea, mysis, early post-larvae (PL 1~10), late post-larvae (PL
10~20), and juveniles, are susceptible to infection; among
these, the late post-larvae and juveniles are more-highly susceptible than are the other stages [21]. Based on the results of
the present study, we will attempt to confirm that the mAb
developed against the VP28 subunit is a viable choice of a
method for controlling and treating WSSV infection. Postlarval survival was many-fold higher when compared to the
control organisms, which indicates that the mAb is able to
protect P. monodon post-larvae from WSSV infection by enhancing their defense mechanisms. Moreover, antibody-treated
shrimp had better growth rates compared to the controls. This
is evidence of consequences of the health status of the shrimp,
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and the antibody-plus-virus treatment indirectly indicates that
WSSV infection causes a drop in weight gain. The possible
explanation of survival of virus-treated shrimp may be the
existence of maternal antibodies or some other kind of innate
immune response in those individuals.
Accumulated neutralization experiments proved that VP28
is a spike peptide present on the WSSV envelope which plays
a pivotal role in systemic infection [15, 20]. The VP28 peptide
was selected as the antigen from which to develop the mAb in
this study, and it was also expressed in high numbers in E. coli
with the pET 28a vector. Moreover, soluble protein expression was used as a source of antigen to produce the mAb,
because soluble antigens normally provoke better antigenicity
than do insoluble antigens [8]. Previous oral-treatment studies
also revealed that a mixture of VP19 and VP28 antibodytreated groups had comparatively lower relative survival rates
than did the group vaccinated with VP28 alone, and those
results revealed that a low titer of VP28 in the mixture and a
lack of protection when using VP19 alone clearly reveal that
the VP28 peptide plays a vital role in WSSV infection rather
than having a synergistic effect [14]. In the present study,
juveniles obtained from antibody-treated post-larvae exposed
to the virus had 50% survival after 30 days of continuous virus
exposure; on the other hand, juveniles obtained from the control tank showed 100% mortality within 20 days, which illustrates that vaccinating shrimp with the mAb during the
post-larval stage is highly effective during their late growth
period and reveals that shrimp have a specific memory response against WSSV. The antibody + virus-treated juveniles
from the antibody and control tanks showed greater than 80%
and 50% survival rates, respectively. Cellular structural biology studies demonstrated that WSSV lesions are first observed in the stomach, gills, and cuticular epidermis of shrimp
and subsequently spread throughout the body, so the routes of
immunization via immersion and oral intake are better choices
when compared to the injection mode.
Losses in antibody-treated groups may have been due to
some other virus infections or cannibalism; we observed that
compared to the virus-infected group, the healthy control and
antibody-treated groups had higher levels of cannibalism (data
not shown). Hence, we suggest that after 20 days in the
rearing tank, separation of shrimp based on size is a suitable
method for obtaining better yields. In general, mixed virus
infection is more commonly seen in shrimp disease [10],
hence we suggest that before introducing post-larvae to a
rearing pond, it is essential to evaluate different commercially
available virus diagnoses. Passive immunity against shrimp
diseases has not been well characterized. Kim et al. reported
that the increase in the pAb in chicken egg yolk against WSSV
viral protein truncated against VP28 and VP19 was efficient in
preventing WSSV infection in P. chinensis [5]. Our therapeutic trial proved that passive immunization within 5 days of
infection is able to prevent further shrimp losses. If mass
vaccinations are carried out using this mAb, it may be possible
to prevent or control further losses due to WSSV virus infection.
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The administration of substances is claimed to be one of the
major limitations for treating or preventing aquatic diseases,
and it also is the key factor determining the success or failure
of a substance. In general, 3 different routes of vaccination are
employed for aquatic organisms especially fish and shrimp,
including injection, immersion, and oral routes, each of which
has certain advantages and drawbacks [12]. Accumulating
evidence from reports on injection methods reveals that they
are most effective, but they cause great stresses to organisms,
are very difficult to handle, are labor intensive, require skilled
persons, and are time consuming and costly; moreover, it is
impossible to inject small shrimp like post-larvae, and after
this stage, it is very difficult to capture each shrimp from a
culture pond and immunize it. Immersion is the preferred
route of administration for post-larvae, however it requires a
large quantity of substances. Even though the oral route of
administration is very easy, its success has been very limited,
even though this is the natural route of entry of pathogens.
In conclusion, the present study confirms that Penaeus
monodon has a specific memory against WSSV infection; the
monoclonal antibody produced against the VP28 protein was
efficient in inducing a defense mechanism against the WSSV
pathogen in post-larvae and juveniles; and WSSV infection
leads to reductions in shrimp growth during the early developmental stages.
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